A5018617106- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Breast Lesions and Carcinomas
- Estrogen and related hormone effects
- Cancer-related Molecular Pathways
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- Monoclonal and Polyclonal Antibodies Research
- FOXO transcription factor regulation
- Gene expression and cancer classification
- Cancer Immunotherapy and Biomarkers
- Cancer Risks and Factors
- Chemotherapy-induced cardiotoxicity and mitigation
- Radiopharmaceutical Chemistry and Applications
- Bone health and treatments
- PI3K/AKT/mTOR signaling in cancer
- Colorectal Cancer Treatments and Studies
- Global Cancer Incidence and Screening
- Chemotherapy-related skin toxicity
- Neutropenia and Cancer Infections
The University of Texas MD Anderson Cancer Center
2016-2025
Breast Cancer Care
2003-2023
Institut Gustave Roussy
2005-2023
Baylor College of Medicine
1998-2023
University of Michigan–Ann Arbor
2005-2023
Yale University
1996-2023
Cleveland Clinic
2005-2023
Roswell Park Comprehensive Cancer Center
2010-2023
Loyola University Medical Center
2015-2023
University of Kansas Medical Center
2023
Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target rapamycin (mTOR) intracellular signaling pathway. In early studies, mTOR inhibitor everolimus added showed antitumor activity.In this phase 3, randomized trial, we compared and exemestane versus placebo (randomly assigned a 2:1 ratio) 724 patients hormone-receptor-positive advanced who had recurrence or progression while receiving previous nonsteroidal aromatase adjuvant setting treat...
Purpose Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone (PR), and human epidermal growth factor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherapy survival between patients with TNBC non-TNBC. Patients Methods Analysis a prospectively collected clinical database was performed. We included 1,118 who received at M.D. Anderson Cancer Center for stage I-III from 1985 2004 whom complete information were...
Abstract Purpose: Molecular classification of breast cancer has been proposed based on gene expression profiles human tumors. Luminal, basal-like, normal-like, and erbB2+ subgroups were identified shown to have different prognoses. The goal this research was determine if these molecular subtypes also respond differently preoperative chemotherapy. Experimental Design: Fine needle aspirations 82 cancers obtained before starting paclitaxel followed by 5-fluorouracil, doxorubicin,...
The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) negative human epidermal growth factor 2 (HER2).In this randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy safety selective CDK4/6 inhibitor ribociclib combined with letrozole first-line treatment 668 postmenopausal women HR-positive, HER2-negative recurrent metastatic who had...
By 2030, the United States' population will increase to approximately 365 million, including 72 million older adults (age > or = 65 years) and 157 minority individuals. Although cancer incidence varies by age race, impact of demographic changes on has not been fully characterized. We sought estimate number patients diagnosed in States through 2030 race.Current demographic-specific rates were calculated using Surveillance Epidemiology End Results database. Population projections from Census...
To measure residual disease after neoadjuvant chemotherapy in order to improve the prognostic information that can be obtained from evaluating pathologic response.Pathologic slides and reports were reviewed 382 patients two different treatment cohorts: sequential paclitaxel (T) then fluorouracil, doxorubicin, cyclophosphamide (FAC) 241 patients; a single regimen of FAC 141 patients. Residual cancer burden (RCB) was calculated as continuous index combining measurements primary tumor (size...
PURPOSE: To assess patient and tumor characteristics associated with a complete pathologic response (pCR) in both the breast axillary lymph node specimens outcome of patients found to have pCR after neoadjuvant chemotherapy for locally advanced cancer (LABC). PATIENTS AND METHODS: Three hundred seventy-two LABC received treatment two prospective trials using four cycles doxorubicin-containing chemotherapy. Patients had total mastectomy dissection or segmental followed by more additional then...
Purpose The objective of this study was to determine whether the addition trastuzumab chemotherapy in neoadjuvant setting could increase pathologic complete response (pCR) rate patients with human epidermal growth factor receptor 2 (HER2) –positive disease. Patients and Methods Forty-two HER2-positive disease operable breast cancer were randomly assigned either four cycles paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide or same simultaneous weekly for 24 weeks. primary...
Metastatic breast cancer (MBC) is incurable; its treatment palliative. We investigated whether the presence of circulating tumor cells (CTCs) predicts efficacy, progression-free survival (PFS), and overall (OS) in patients with newly diagnosed MBC who were about to start first-line therapy.One hundred seventy-seven measurable enrolled onto a prospective study. Eighty-three 177 entering treatment, these are focus this analysis. CTCs from 7.5 mL whole blood drawn before initiation (baseline)...
Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy multiple HER2-targeted agents limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. We randomly assigned patients HER2-positive previously treated trastuzumab, pertuzumab, and trastuzumab emtansine, had or did not brain metastases, to receive either tucatinib placebo, in combination...
Bisphosphonates such as pamidronate disodium inhibit osteoclast-induced bone resorption associated with cancer that has metastasized to bone.
Abstract Extracellular interaction between programmed death ligand-1 (PD-L1) and cell protein-1 (PD-1) leads to tumour-associated immune escape. Here we show that the immunosuppression activity of PD-L1 is stringently modulated by ubiquitination N -glycosylation. We glycogen synthase kinase 3β (GSK3β) interacts with induces phosphorylation-dependent proteasome degradation β-TrCP. In-depth analysis N192, N200 N219 glycosylation suggests antagonizes GSK3β binding. In this regard, only...
Population studies have suggested that metformin use in diabetic patients decreases cancer incidence and mortality. Metformin inhibits the growth of cells vitro tumors vivo. However, there is little clinical data to support this. Our purpose was determine whether associated with a change pathologic complete response (pCR) rates breast receiving neoadjuvant chemotherapy.We identified 2,529 who received chemotherapy for early-stage between 1990 2007. Patients were compared by groups: 68 taking...
Purpose: To explore whether a cross-talk exists between PARP inhibition and PD-L1/PD-1 immune checkpoint axis, determine blockade of potentiates inhibitor (PARPi) in tumor suppression.Experimental Design: Breast cancer cell lines, xenograft tumors, syngeneic tumors treated with PARPi were assessed for PD-L1 expression by immunoblotting, IHC, FACS analyses. The phospho-kinase antibody array screen was used to the underlying mechanism PARPi-induced upregulation. therapeutic efficacy alone, or...
Metaplastic breast cancers (MBC) are aggressive, chemoresistant tumors characterized by lineage plasticity. To advance understanding of their pathogenesis and relatedness to other cancer subtypes, 28 MBCs were compared with common using comparative genomic hybridization, transcriptional profiling, reverse-phase protein arrays sequencing for mutations. showed unique DNA copy number aberrations cancers. PIK3CA mutations detected in 9 19 (47.4%) versus 80 232 hormone receptor-positive (34.5%; P...
Answer questions and earn CME/CNE The revision of the eighth edition primary tumor, lymph node, metastasis (TNM) classification American Joint Commission Cancer (AJCC) for breast cancer was determined by a multidisciplinary team experts. panel recognized need to incorporate biologic factors, such as tumor grade, proliferation rate, estrogen progesterone receptor expression, human epidermal growth factor 2 (HER2) gene expression prognostic panels into staging system. AJCC levels evidence...
Taxol, an antimicrotubule agent, has shown promise for efficacy in treatment of breast cancer, but severe hypersensitivity reactions led to cessation many phase I clinical trials. Consequently, investigators and the National Cancer Institute recommended that II studies this agent use 24-hour infusions antiallergic medications. Using a premedication regimen effective preventing reactions, we have performed trial taxol patients with metastatic cancer. Taxol was administered 25 at dose 250 mg/m...
Breast cancer is a major public health problem worldwide. Management of breast was last reviewed in the Journal 1992.1 The accumulation new biologic information, results recent clinical trials, and availability diagnostic therapeutic tools make it appropriate to review subject again.EpidemiologyThe incidence United States has been increasing gradually for past three decades.2,3 It estimated that 181,600 cases were diagnosed 1997 44,190 people would die during same .
Abstract BACKGROUND Male breast carcinoma is an uncommon disease, and most previous studies have been single‐institution series that were limited by extremely small sample sizes. The goals of the current study to fill in major gaps knowledge regarding incidence, presenting characteristics, prognostic factors, survival rates male determine how differs between men women. METHODS Data from National Cancer Institute Surveillance, Epidemiology, End Results 1973–1998 database used. Age‐adjusted...